Abstract:Dendritic cells (DCs) play a pivotal role in initiating anti-tumor immune responses. Our group has developed an adoptive cellular transfer therapy (ACT) that significantly increases the infiltration of DCs and T cells into tumors, markedly enhancing survival in murine brain tumor models. However, tumors develop mechanisms to restrict the immune surveillance and the efficacy of immunotherapy, leading to tumor escape. In this study, we identified a mechanism involving DC dysfunction in ACT-escaped brain tumors. The finding that DCs are enriched after ACT treatment prompts an investigation into whether DC function is impaired in ACT-escaped tumors. Our results showed that DCs from both primary and ACT-escaped tumors were dysfunctional in their ability to activate T cells when co-cultured with tumor-reactive T cells or OT1 T cells. RNA-seq data revealed that, compared to primary tumor DCs, ACT-escaped tumor DCs exhibited a more pronounced reduction in conventional DC markers and antigen-presenting genes, alongside increased tolerance markers. Gene set enrichment analysis indicated that epithelial-mesenchymal transition (EMT) and hypoxia pathways were significantly enriched in ACT-escaped tumor DCs, suggesting divergent DC dysfunction mechanisms in primary versus escaped tumors. The anti-tumor role of DCs is primarily exerted through the activation of tumor-reactive T cells. Therefore, we assessed the cytotoxicity and exhaustion status of T cells in tumors. Surprisingly, we found that T cells from ACT-escaped tumors exhibited significantly higher levels of cytotoxicity and lower levels of T cell exhaustion compared to primary tumors. This suggests a T cell exhaustion-independent mechanism in ACT-escaped tumors. We further demonstrated that T cells in ACT-escaped tumor are mainly sourced from the adoptive transferred T cells, which recognize primary tumor antigens but not escaped tumor antigens. These results suggest that a combined mechanism of tumor antigen shifting and impaired DC function leads to a failure of antigen spreading and tumor eradication.

Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton.

Impaired function of dendritic cells within the tumor microenvironment

Disturbance of Differentiation and Maturation of Dendritic Cells and Tumor Escape

Dysfunction of dendritic cells in tumor microenvironment and immunotherapy

Hepatocellular Carcinoma Cells Deteriorate the Biophysical Properties of Dendritic Cells

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy

Transforming Growth Factor-Β1 Deteriorates Microrheological Characteristics and Motility of Mature Dendritic Cells in Concentration-Dependent Fashion.

Biophysical Properties And Motility Of Human Mature Dendritic Cells Deteriorated By Vascular Endothelial Growth Factor Through Cytoskeleton Remodeling

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Interleukin-10 Reorganizes The Cytoskeleton Of Mature Dendritic Cells Leading To Their Impaired Biophysical Properties And Motilities

Tumor-initiating Stem Cell Shapes Its Microenvironment into an Immunosuppressive Barrier and Pro-Tumorigenic Niche.

Biomechanical Alterations of Dendritic Cells by Co-Culturing with K562 CML Cells and Their Potential Role in Immune Escape.

Dendritic cell biology and its role in tumor immunotherapy

Role of tumor-derived exosomes mediated immune cell reprograming in cancer

Differentiation and Immunological Function of MDSC-Derived Dendritic Cells

Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy

Dendritic cells dysfunction in tumor-draining lymph nodes

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment

Tmic-09. Dendritic Cell Dysfunction Restricts Tumor Antigen Spreading In Adoptive Cellular Transfer Therapy-Escaped Gliomas: Implications For Tumor Immune Evasion